Anaptysbio annual operating margin
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Anaptysbio's operating margin was 20.42% for fiscal 2025.
View full Anaptysbio company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 20.42% | +146.35 pp |
| 2024 | 2024-12-31 | −125.93% | +832.34 pp |
| 2023 | 2023-12-31 | −958.27% | +161.14 pp |
| 2022 | 2022-12-31 | −1,119.41% | −1029.48 pp |
| 2021 | 2021-12-31 | −89.93% | −58.09 pp |
| 2020 | 2020-12-31 | −31.84% | +1311.06 pp |
| 2019 | 2019-12-31 | −1,342.90% | −8.46 pp |
| 2018 | 2018-12-31 | −1,334.44% | −1046.63 pp |
| 2017 | 2017-12-31 | −287.81% | −269.68 pp |
| 2016 | 2016-12-31 | −18.13% | +0.78 pp |
| 2015 | 2015-12-31 | −18.91% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q1 2026 | 2026-03-31 | −135.53% | −36.37 pp |
| Q4 2025 | 2025-12-31 | 61.80% | +84.23 pp |
| Q3 2025 | 2025-09-30 | 45.47% | +121.29 pp |
| Q2 2025 | 2025-06-30 | −117.55% | +249.97 pp |
| Q1 2025 | 2025-03-31 | −99.16% | +488.67 pp |
| Q4 2024 | 2024-12-31 | −22.43% | +445.48 pp |
| Q3 2024 | 2024-09-30 | −75.81% | +1061.38 pp |
| Q2 2024 | 2024-06-30 | −367.52% | +792.68 pp |
| Q1 2024 | 2024-03-31 | −587.84% | +2643.67 pp |
| Q4 2023 | 2023-12-31 | −467.91% | −86.40 pp |
| Q3 2023 | 2023-09-30 | −1,137.19% | +1154.61 pp |
| Q2 2023 | 2023-06-30 | −1,160.20% | +1125.90 pp |
| Q1 2023 | 2023-03-31 | −3,231.51% | +41.58 pp |
| Q4 2022 | 2022-12-31 | −381.51% | +2700.29 pp |
| Q3 2022 | 2022-09-30 | −2,291.80% | −2259.43 pp |
| Q2 2022 | 2022-06-30 | −2,286.10% | −2284.33 pp |
| Q1 2022 | 2022-03-31 | −3,273.09% | −3109.84 pp |
| Q4 2021 | 2021-12-31 | −3,081.80% | −3137.38 pp |
| Q3 2021 | 2021-09-30 | −32.37% | +35.98 pp |
| Q2 2021 | 2021-06-30 | −1.78% | +740.16 pp |
| Q1 2021 | 2021-03-31 | −163.25% | +369.89 pp |
| Q4 2020 | 2020-12-31 | 55.57% | +393.31 pp |
| Q1 2020 | 2020-03-31 | −68.35% | +170.01 pp |
| Q4 2019 | 2019-12-31 | −741.93% | −705.43 pp |
| Q2 2019 | 2019-06-30 | −533.14% | −417.89 pp |
| Q3 2018 | 2018-09-30 | −337.74% | −304.29 pp |
| Q4 2017 | 2017-12-31 | −238.37% | −278.76 pp |
| Q2 2017 | 2017-06-30 | −36.50% | −13.09 pp |
| Q4 2016 | 2016-12-31 | −115.25% | — |
| Q3 2016 | 2016-09-30 | −33.45% | — |
| Q2 2016 | 2016-06-30 | 40.39% | — |
| Q1 2016 | 2016-03-31 | −23.41% | — |
Over the last five reported fiscal years, Anaptysbio's operating margin increased from −31.84% to 20.42%, a change of +52.25 percentage points. The latest reported quarter, Q1 2026, shows −135.53%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anaptysbio filings at SEC.gov ↗